Northwick Park Hospital
Harrow, Middx, HA1 3UJ, United Kingdom
NCT Number: NCT02527616
This is a single-blinded, randomised, crossover investigation comparing the investigational device using intra-coronary (IC) Adenosine infusion to the standard intra-venous (IV) infusion method used for obtaining FFR measurements. All subjects requiring on a clinical basis a pressure wire assessment of intermediate coronary artery stenosis(es) will be eligible to take part in the investigation.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Harrow, Middx, HA1 3UJ, United Kingdom
Coronary artery disease is the most common type of heart disease that affects millions of people worldwide. It is caused by a narrowing or blocking of the arteries (known as stenosis) due to plaque, which restricts blood flow and reduces the amount of oxygen to the heart.
Over the past decade, fractional flow reserve (FFR) measurement has been increasingly used in cardiac catheterization laboratories, providing a straightforward and readily available quantitative assessment of the functional severity of a coronary artery stenosis, as the ability of the cardiologist to discriminate between stenoses that can cause ischemia and those that are physiologically insignificant on the basis of coronary angiography alone is limited.
Measuring FFR determines the ratio between the maximum achievable blood flow in a diseased or narrowed coronary artery and the maximum blood flow in a normal coronary artery. This ratio represents the potential decrease in coronary flow distal to the coronary stenosis.
FFR is easily measured during routine coronary angiography by using a pressure wire to calculate the ratio between the coronary pressure distal to a stenosis or a diseased segment and the aortic pressure under conditions of maximum myocardial hyperemia. An FFR of 1.0 is widely accepted as normal. An FFR lower than 0.80 is generally considered to be associated with coronary ischemia and widely accepted in favour of revascularization over conservative management.
The current standard methods of measuring FFR is to insert a pressure wire into the coronary artery while the hyperaemic agent, normally adenosine, is delivered by continuous intravenous infusion via a central femoral vein, a large ante-cubital peripheral cannula or intra-coronary bolus injection.
The investigational device in this clinical investigation is an FFR catheter being developed by Diasolve Limited; a UK based medical device development company. The FFR catheter is a combined pressure wire and hyperaemic agent delivery catheter, which allows simultaneous delivery of a pressure wire and administration of the hyperaemic agent directly into the coronary ostium or most proximal section of the coronary artery, when performing a FFR measurement using currently available pressure wire systems such as Pressure Wire Certus or Prestige from St Jude Medical.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Prior to randomisation:
-
Exclusion criteria
Cross-over design where FFR is measured twice in the same lesion using standard standard intra-venous (IV) infusion and new method
Other names: HYPEREM™IC, REF: 143836-01 GTIN: 5060420320008., HYPERAEM
Time frame: Intraoperative
The FFR ratio should remain constant when measured by the standard method and the investigational device.
Time frame: Intraoperative
Participants should not experience any additional adverse events during FFR ratio measurement using the investigational device than they do using the standard method.
Time frame: Intraoperative
Maximum hyperaemia may be achieved with a reduced dose of adenosine using the FFR Catheter.
Time frame: Intraoperative
Maximum hyperaemia may be achieved faster using the FFR Catheter
Diasolve Ltd
Industry
A Randomised, Crossover Investigation to Evaluate and Compare the Effectiveness, Safety and Feasibility of a Novel Dedicated Over-The-Wire FFR Infusion Microcatheter (HYPEREM™IC) for Measuring Fractional Flow Reserve (FFR) Using Intra-coronary Non-weight Adjusted Adenosine Infusion With the Standard Intra-venous Administration of Adenosine, in Subjects With Intermediate Coronary Artery Stenosis.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03188705
Arterial Occlusive Diseases, Arteriosclerosis
Lancaster, Pennsylvania, United States
View Trial DetailsNCT07468955
Arterial Occlusive Diseases, Arteriosclerosis
Kütahya, Center, Turkey (Türkiye)
View Trial DetailsNCT06029517
Arterial Occlusive Diseases, Arteriosclerosis
Buffalo, New York, United States
View Trial DetailsNCT04058990
Arterial Occlusive Diseases, Arteriosclerosis
Kitakyushu, Fukuoka, Japan
View Trial Details